Skip to main content
Erschienen in: Medical Oncology 5/2012

01.12.2012 | Original Paper

BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity

verfasst von: Abida Juwle, Dhananjaya Saranath

Erschienen in: Medical Oncology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

We examined BRCA1/2 mutations and single nucleotide polymorphisms (SNPs) for identification of BRCA1 haplotypes, in early-onset breast cancer patients and their relatives, sporadic breast cancer patients, and unrelated normal healthy females, of Indian ethnicity. Peripheral blood DNA was amplified by polymerase chain reaction, at BRCA1/2 coding exons and subject to nucleotide sequencing using ABI 3100 Genetic Analyzer. We observed BRCA1/BRCA2 mutations in 52 % early-onset breast cancer patients and in 57 % relatives. Deleterious mutations detected in early-onset patients and relatives were 187delAG, 632insT, 1052delT, Q759X, Q780X, R1203X, 5154delC, IVS14 + 1G > A, IVS17 + 1G > T, and 632insT in BRCA1 gene; and 4075delGT, 5076delAA, 6079delAGTT, and W3127X in BRCA2 gene. A high degree of penetrance of BRCA1/2 gene mutations was observed in the relatives. BRCA1/2 SNPs were identified in the Indian population, and association of BRCA1 haplotypes with breast cancer was investigated. A significantly increased frequency of the SNPs 203G/A, 3624A/G and 7470A/G SNPs in BRCA2 gene was observed in normal controls indicative of a protective effect of the SNPs. BRCA1 haplotype 2 was most frequently observed in our population. Our study indicates a high incidence of BRCA1/BRCA2 gene mutations in the Indian patients. The BRCA1/2 mutations and SNPs are detailed on our website http://​relibrca.​rellife.​com.
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, editors. Globocan 2008 v1.2. In: Cancer incidence and mortality worldwide: IARC Cancer Base No.10 Internet. Lyon France: International Agency for Research in Cancer; 2010. Available from: http://globocan.iarc.fr/. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, editors. Globocan 2008 v1.2. In: Cancer incidence and mortality worldwide: IARC Cancer Base No.10 Internet. Lyon France: International Agency for Research in Cancer; 2010. Available from: http://​globocan.​iarc.​fr/​.
2.
Zurück zum Zitat Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, editors. Cancer Incidence in Five Continents, No. 160. Volume IX. Lyon, France: IARC Scientific Publications; 2007. 896 pp. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, editors. Cancer Incidence in Five Continents, No. 160. Volume IX. Lyon, France: IARC Scientific Publications; 2007. 896 pp.
3.
Zurück zum Zitat Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. In: Cancer incidence in five continents, No. 155. Volume VIII. Lyon, France: IARC Scientific Publications; 2002. 781 pp. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. In: Cancer incidence in five continents, No. 155. Volume VIII. Lyon, France: IARC Scientific Publications; 2002. 781 pp.
4.
Zurück zum Zitat National Cancer Registry Program. Consolidated report of the population based cancer registries. New Delhi: Indian Council of Medical Research; 2001. National Cancer Registry Program. Consolidated report of the population based cancer registries. New Delhi: Indian Council of Medical Research; 2001.
5.
Zurück zum Zitat Dumitrescu RG, Cotarla I. Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med. 2005;9:208–21.PubMedCrossRef Dumitrescu RG, Cotarla I. Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med. 2005;9:208–21.PubMedCrossRef
6.
Zurück zum Zitat Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008;14:7988–99.PubMedCrossRef Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008;14:7988–99.PubMedCrossRef
7.
Zurück zum Zitat Eeles RA. Future possibilities in the prevention of breast cancer intervention strategies in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2000;2:283–90.PubMedCrossRef Eeles RA. Future possibilities in the prevention of breast cancer intervention strategies in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2000;2:283–90.PubMedCrossRef
9.
Zurück zum Zitat Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998;63:45–51.PubMedCrossRef Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998;63:45–51.PubMedCrossRef
10.
Zurück zum Zitat Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–7.PubMedCrossRef Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–7.PubMedCrossRef
11.
Zurück zum Zitat Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–8.PubMedCrossRef Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–8.PubMedCrossRef
12.
Zurück zum Zitat Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 1996;56:3663–5.PubMed Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 1996;56:3663–5.PubMed
13.
Zurück zum Zitat Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H, Eyfjörd JE. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60:1079–84.PubMed Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H, Eyfjörd JE. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60:1079–84.PubMed
14.
Zurück zum Zitat Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, et al. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treat. 2004;88:177–86.PubMedCrossRef Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, et al. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treat. 2004;88:177–86.PubMedCrossRef
15.
Zurück zum Zitat Kumar BV, Lakhotia S, Ankhatil R, Madhavan J, Jayaprakash PG, Nair MK, Somasundaram K. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families. Cancer Biol Ther. 2002;1:18–21.PubMed Kumar BV, Lakhotia S, Ankhatil R, Madhavan J, Jayaprakash PG, Nair MK, Somasundaram K. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families. Cancer Biol Ther. 2002;1:18–21.PubMed
16.
Zurück zum Zitat Saxena S, Szabo CI, Chopin S, Barjhoux L, Sinilnikova O, Lenoir G, Goldgar DE, Bhatanager D. BRCA1 and BRCA2 in Indian breast cancer patients. Hum Mutat. 2002;20:473–4.PubMedCrossRef Saxena S, Szabo CI, Chopin S, Barjhoux L, Sinilnikova O, Lenoir G, Goldgar DE, Bhatanager D. BRCA1 and BRCA2 in Indian breast cancer patients. Hum Mutat. 2002;20:473–4.PubMedCrossRef
17.
Zurück zum Zitat Saxena S, Chakraborthy A, Kauhsal M, Kotwal S, Bhatanager D, Mohil R, Chintamani C, Aggarwal AK, et al. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in northern India. BMC Med Genet. 2006;7:75.PubMedCrossRef Saxena S, Chakraborthy A, Kauhsal M, Kotwal S, Bhatanager D, Mohil R, Chintamani C, Aggarwal AK, et al. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in northern India. BMC Med Genet. 2006;7:75.PubMedCrossRef
18.
Zurück zum Zitat Valarmathi MT, Sawhney M, Deo SSV, Shukla NK, Das SN. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast-ovarian cancer families. Hum Mutat. 2004;23:205.PubMedCrossRef Valarmathi MT, Sawhney M, Deo SSV, Shukla NK, Das SN. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast-ovarian cancer families. Hum Mutat. 2004;23:205.PubMedCrossRef
19.
Zurück zum Zitat Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation. J Biosci. 2009;34:415–22.PubMedCrossRef Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation. J Biosci. 2009;34:415–22.PubMedCrossRef
20.
Zurück zum Zitat Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V, Shanta V. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev. 2003;4:203–8.PubMed Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V, Shanta V. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev. 2003;4:203–8.PubMed
21.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–90.PubMedCrossRef Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–90.PubMedCrossRef
22.
Zurück zum Zitat Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, Ward BE, Pruss D, et al. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res. 2005;65:10096–103.PubMedCrossRef Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, Ward BE, Pruss D, et al. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res. 2005;65:10096–103.PubMedCrossRef
23.
Zurück zum Zitat Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60 % of ovarian cancer and 30 % of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997;60:505–14.PubMed Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60 % of ovarian cancer and 30 % of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997;60:505–14.PubMed
24.
Zurück zum Zitat Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H, Eyfjörd JE. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60:1079–84.PubMed Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H, Eyfjörd JE. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60:1079–84.PubMed
25.
Zurück zum Zitat Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst. 2001;93:1215–23.PubMedCrossRef Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst. 2001;93:1215–23.PubMedCrossRef
26.
Zurück zum Zitat Malone KE, Daling JR, Neal C, Suter NM, O’Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000;88:1393–402.PubMedCrossRef Malone KE, Daling JR, Neal C, Suter NM, O’Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000;88:1393–402.PubMedCrossRef
27.
Zurück zum Zitat Shih HA, Couch FJ, Nathason KL, Blackwood MA, Rebbeck TR, Armstrong KA, Calzone K, Stopfer J, et al. BRCA1 and BRCA2 mutations frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol. 2002;20:994–9.PubMedCrossRef Shih HA, Couch FJ, Nathason KL, Blackwood MA, Rebbeck TR, Armstrong KA, Calzone K, Stopfer J, et al. BRCA1 and BRCA2 mutations frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol. 2002;20:994–9.PubMedCrossRef
28.
Zurück zum Zitat Shih HA, Nathanson KL, Seal S, Blackwood MA, Rebbeck TR, Armstrong KA, Weber BL. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res. 2000;6:4259–64.PubMed Shih HA, Nathanson KL, Seal S, Blackwood MA, Rebbeck TR, Armstrong KA, Weber BL. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res. 2000;6:4259–64.PubMed
29.
Zurück zum Zitat Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet. 2004;41:492–507.PubMedCrossRef Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet. 2004;41:492–507.PubMedCrossRef
30.
Zurück zum Zitat Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations risk factor analysis and implications for genetic testing. JAMA. 1997;278:1242–50.PubMedCrossRef Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations risk factor analysis and implications for genetic testing. JAMA. 1997;278:1242–50.PubMedCrossRef
31.
Zurück zum Zitat Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, Foo D, Hau DD, et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res. 2010;70:4880–90.PubMedCrossRef Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, Foo D, Hau DD, et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res. 2010;70:4880–90.PubMedCrossRef
32.
Zurück zum Zitat Ruffner H, Joazeiro CAP, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. PNAS USA. 2001;98:5134–9.PubMedCrossRef Ruffner H, Joazeiro CAP, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. PNAS USA. 2001;98:5134–9.PubMedCrossRef
33.
Zurück zum Zitat Dunning AM, Chiano M, Smith NR, Dearden J, Gore M, Oakes S, Wilson C, Stratton M, et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet. 1997;6:285–9.PubMedCrossRef Dunning AM, Chiano M, Smith NR, Dearden J, Gore M, Oakes S, Wilson C, Stratton M, et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet. 1997;6:285–9.PubMedCrossRef
34.
Zurück zum Zitat Durocher F, Shattuck-Eidens D, McClure M, Labrie F, Skolnick MH, Goldgar DE, Simard J. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet. 1996;5:835–42.PubMedCrossRef Durocher F, Shattuck-Eidens D, McClure M, Labrie F, Skolnick MH, Goldgar DE, Simard J. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet. 1996;5:835–42.PubMedCrossRef
35.
Zurück zum Zitat Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet. 1994;8:399–404.PubMedCrossRef Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet. 1994;8:399–404.PubMedCrossRef
36.
Zurück zum Zitat De Silva W, Karunanayake EH, Tennekoon KH, Allen M, Amarasinghe I, Angunawala P, Ziard MH. Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals. BMC Cancer. 2008;8:214.PubMedCrossRef De Silva W, Karunanayake EH, Tennekoon KH, Allen M, Amarasinghe I, Angunawala P, Ziard MH. Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals. BMC Cancer. 2008;8:214.PubMedCrossRef
37.
Zurück zum Zitat Toh GT, Kang P, Lee SSW, Lee DSC, Lee SY, Selamat S, Mohd Taib NA, Yoon SY, et al. BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PLoS One. 2008;3:e2024.PubMedCrossRef Toh GT, Kang P, Lee SSW, Lee DSC, Lee SY, Selamat S, Mohd Taib NA, Yoon SY, et al. BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PLoS One. 2008;3:e2024.PubMedCrossRef
38.
Zurück zum Zitat Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet. 1995;9:439–43.PubMedCrossRef Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet. 1995;9:439–43.PubMedCrossRef
39.
Zurück zum Zitat Maurice A, Evans DG, Shenton A, Ashcroft L, Baildam A, Barr L, Byrne G, Bundred N, et al. Screening younger women with a family history of breast cancer—does early detection improve outcome? Eur J Cancer. 2006;42:1385–90.PubMedCrossRef Maurice A, Evans DG, Shenton A, Ashcroft L, Baildam A, Barr L, Byrne G, Bundred N, et al. Screening younger women with a family history of breast cancer—does early detection improve outcome? Eur J Cancer. 2006;42:1385–90.PubMedCrossRef
40.
Zurück zum Zitat Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol. 2009;20:1505–10.PubMedCrossRef Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol. 2009;20:1505–10.PubMedCrossRef
Metadaten
Titel
BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity
verfasst von
Abida Juwle
Dhananjaya Saranath
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 5/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0294-9

Weitere Artikel der Ausgabe 5/2012

Medical Oncology 5/2012 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.